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Background. Alport syndrome is a clinically and genetically
heterogeneous nephropathy. The majority of cases are trans-
mitted as an X-linked semidominant condition due to COL4A5
mutations. In this form males are more severely affected than
females. Less than 10% of cases are autosomal recessive due
to mutation in either COL4A3 or COL4A4. In this rarer form,
both males and females are severely affected. Only two cases of
autosomal-dominant Alport syndrome have been reported, one
due to a COL4A3 mutation and the other due to a COL4A4 mu-
tation. Because of the paucity of the reported families, the nat-
ural history of autosomal-dominant Alport syndrome is mostly
unknown.
Methods. Four families with likely autosomal-dominant Al-
port syndrome were investigated. COL4A3 and COL4A4 genes
were analyzed by denaturing high-performance liquid chro-
matography (HPLC). Automated sequencing was performed
to identify the underlying mutation.
Results. Two families had a mutation in the COL4A4 gene
and two in the COL4A3. Accurate clinical evaluation of family
members showed interesting results. Affected individuals (22
persons) had a wide range of phenotypes from end-stage renal
disease (ESRD) in the fifth decade to a nonprogressive isolated
microhematuria. Finally, three heterozygous individuals (90, 22
and 11 years old, respectively) were completely asymptomatic.
Conclusion. This paper demonstrated that patients affected
by autosomal-dominant Alport syndrome have a high clinical
variability. Moreover, a reduced penetrance of about 90% (3
of 25) may be considered for the assessment of recurrence risk
during genetic counseling of these families.
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Alport syndrome is a progressive inherited glomeru-
lonephritis often associated with deafness and/or ocu-
lar lesions. Alport syndrome accounts for 1% to 2%
of all patients who start renal replacement therapy in
Europe, with an estimated gene frequency of about 1
in 5000 [1, 2]. It was originally reported in 1927 by
Alport [3]. In 1976, Alport syndrome was described as
an autosomal-dominant condition [4]. The genetics of
Alport syndrome was a hotly debated topic, until the sem-
inal report of O’Neill in 1978 [5], followed by Hasstedt
[6] in 1983. This led directly to the mapping of the major
Alport locus to the X-chromosome by linkage analysis
[7], setting the stage for the identification of mutations in
COL4A5 by Barke et al [8], following the discovery of
the COL4A5 gene by Hostikka et al [9] and Myers et al
[10]. The inheritance of Alport syndrome was thus estab-
lished as X-linked semidominat (OMIM #305010). In this
form, 70% of affected males reach end-stage renal dis-
ease (ESRD) before the age of 30 years (juvenile form),
while only few cases (30%) progress toward ESRD after
30 years (rare adult form) [11]. Usually, females have only
microhematuria.
In 1993, mutations in both the COL4A4 and COL4A3
genes were reported in the less frequent autosomal-
recessive form of Alport syndrome (OMIM #203780)
[12–14]. Usually in this form, females are as severely af-
fected as males, both reaching ESRD in the first or second
decade of life. Heterozygous parents may be completely
asymptomatic or may have isolated microhematuria.
The existence of a pure autosomal-dominant form
(OMIM #104200) has been questioned for decades. Ac-
tually, Feingold et al [15] presented convincing evidence
of an autosomal-dominant form of Alport syndrome in
their paper, and an autosomal-dominant form of Alport
syndrome was one of the six types of the disease in
the provisional classification system proposed by Atkin,
Gregory, and Border [16]. Only recently, the molecular
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basis of this form has been clarified. One family has a
COL4A3 mutation [17, 18] and another family has a
COL4A4 mutation [19]. More recently, we described one
additional family and three sporadic cases due to het-
erozygous mutation in COL4A3 or COL4A4 genes [20].
In this study, we present four large families with
autosomal-dominant transmission and mutations in both
the COL4A3 (two families) and the COL4A4 gene (two
other families). Accurate clinical analysis was performed
in 25 heterozygous individuals in order to define the nat-
ural clinical history of the autosomal-dominant form.
METHODS
Mutation analysis
Blood samples were collected from affected and
healthy family members. Genomic DNA was isolated
from peripheral blood leukocytes of the patients ac-
cording to standard methods [21]. All the COL4A3
and COL4A4 exons were amplified using primers and
polymerase chain reaction (PCR) conditions as already
described [20]. Mutation analysis was performed by de-
naturing high-performance liquid chromatography (DH-
PLC) using the Transgenomic WAVETM (Transgenomic,
San Jose, CA, USA). PCR products were denatured at
95◦C, reannealed at 65◦C for 10 minutes, and cooled
to 4◦C to generate heteroduplexes. The optimal col-
umn temperature for fragments analysis was calcu-
lated using the WaveMaker Software (Transgenomic).
DHPLC analysis was performed at the melting tempera-
ture of 57◦C for exon 32 (COL4A4), of 60◦C for exon 48
(COL4A4), of 62◦C for exon 42 (COL4A3), and finally
at the melting temperature of 59◦C for exon 37 of the
COL4A3 gene. Direct sequencing of the purified PCR
products was performed in both directions (PE Big Dye
Terminator Cycle Sequencing Kit; Applied Biosystems,
Foster City, CA, USA) on an ABI310 Automated Se-
quencer and analyzed with the Sequencer software.
Segregation analysis
Segregation analysis was performed by restriction anal-
ysis (using AvaII and NlaIII restriction enzymes) when-
ever possible (families 1 and 4) or by direct sequencing
(family 2). In family 3, segregation analysis was per-
formed by DHPLC.
RESULTS
Family 1
In family 1 (LOV), the index case was a 31-year-old
woman with microhematuria since age 13 years (Fig. 1A).
Proteinuria was absent. Her blood pressure and re-
nal function was normal. Electron microscopy of re-
nal biopsy, performed at age 30 years, showed split-
ting, thickening, and thinning of the glomerular base-
ment membrane (GBM), suggesting a diagnosis of Alport
syndrome. She had a normal audiogram and no ocular
signs of the disease. Her father was transplanted at the
age of 52 years. Her son (9 months old) showed microhe-
maturia. A paternal uncle showed microhematuria and
slightly impaired renal function by the age of 59 years.
The paternal grandmother was said to have died at age
41 with chronic renal failure (CRF).
DHPLC analysis of exon 32 of COL4A4 showed addi-
tional heteroduplex peaks. Sequencing analysis resulted
in the identification of a COL4A4 mutation, which caused
a glycine substitution in the collagenous domain of the
protein (c.2869G>C, p.G957R). This mutation was also
present in the father, the son, and the paternal uncle.
The mutation was absent in the paternal healthy aunt
(Fig. 1A).
Family 2
In family 2 (BRD), the proband was a 45-year-old man
with microhematuria, episodes of macrohematuria, and
with normal renal function (Fig.1B). A renal biopsy at age
37 years revealed GBM thickening and splitting, suggest-
ing a diagnosis of Alport syndrome (Fig. 2A). He was
also affected by bilateral sensorineural hypoacusis. His
elder son (13 years old) showed microhematuria by the
age of 3 years with episodes of macrohematuria. His renal
function was normal and he had neither ocular signs nor
sensorineural deafness. A 51-year-old brother showed
persistent microhematuria with episodes of macrohema-
turia and normal renal function. He also had bilateral
sensorineural hypoacusis.
An additional heteroduplex peak was observed by DH-
PLC analysis of exon 48 of COL4A4 in the index pa-
tient. Sequence analysis resulted in the identification of a
COL4A4 mutation, that caused a cysteine substitution
in the C-terminal noncollagenic region of the protein
(p.C1634S, c.4900 T>A). This mutation was also present
in the affected son, in the affected brother, and in the
completely asymptomatic 90-year-old father. The muta-
tion was absent in the healthy son and in two healthy
sisters (Fig. 1B).
Family 3
In family 3 (CST), the index case was a 55-year-old
man with microhematuria since the age of 18 and pro-
teinuria since the age of 43 years (Fig. 1C). He showed
CRF (blood creatinine 1.9 mg%). A renal biopsy at age 51
years revealed GBM thinning (Fig. 2B). He also had bilat-
eral neurosensorial hypoacusis. His 32-year-old daughter,
a 24-year-old son, and a 21-year-old son had isolated mi-
crohematuria. His 68-year-old sister had CRF and two of
her sons (44 and 37 years old, respectively) had isolated
microhematuria. It was reported that the mother had un-
dergone dialysis since the age of 84 years and had died at
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Fig. 1. Pedigrees of families. Open squares are males and open circles are females. Filled gray squares and circles are individuals with isolated
microhematuria. Filled black squares and circles indicate individuals with microhematuria plus macrohematuria or hypoacusia or renal failure.
White squares and circles indicate individuals without clinical signs of the disease. The arrows indicate the index patients. Mutations are indicated
below each symbol. Symbols are: −, wild-type allele; +, mutated allele. Mutation type and mutated gene are indicated below each pedigree.
the age of 88 years. She also had bilateral sensorineural
hypoacusis.
DHPLC analysis and subsequent direct sequencing of
exon 37 of the COL4A3 gene resulted in the identification
of a mutation, that caused a glycine substitution in the col-
lagenous domain of the protein (p.G1045V, c.3134G>T).
This mutation was present in all the affected family mem-
bers and also in the completely asymptomatic 11-year-old
son also (Fig. 1C).
Family 4
In family 4 (POL), the proband was a 49-year-old man
(Fig. 1D). He had microhematuria since the age of 18
years and proteinuria since age 35 years. Episodes of
macrohematuria occurred at age 45 years. He began to
suffer from a nephrotic syndrome at age 40 years and he
began dialysis at age 45 years. Electron microscopy of re-
nal biopsy performed at age 36 years showed splitting of
the GBM (Fig. 2C). He had a normal audiogram and no
ocular signs of the disease. He had three affected broth-
ers. The first one (46 years old) had CRF (blood creatinine
1.33 mg%) with microhematuria reported since the age
of 20 years, the second (45 years old) had both microhe-
maturia and sensorineural hypoacusis, and the youngest
(36 years old) had isolated microhematuria. The daugh-
ter (20 years old) showed isolated microhematuria since
the age of 20 years. The mother died at the age of 72 years.
She had started dialytic treatment at the age of 70 years.
DHPLC analysis of exon 42 of the COL4A3 gene
showed an additional elution peak. Direct sequencing
resulted in the identification of a mutation, that caused
cause a glycine substitution in the collagenous domain of
the protein (p.G1219C, c.3655 G>T). This mutation was
also present in all the affected family members and in the
still asymptomatic 22-year-old nephew (Fig. 1D).
DISCUSSION
We investigated four families with a likely autosomal-
dominant Alport syndrome. In two of these families, a
male to male transmission (families 2 and 3) strongly sug-
gested autosomal-dominant inheritance.
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Fig. 2. Electron micrographs. Glomerular
basement membrane (GBM) of proband 2
(A), proband 3 (B), and proband 4 (C), and
tubule of proband 4 (D). (A) Note the thick-
ening, the splitting and the thinning of the
GBM. (B) Irregular contour and electron lu-
cent zones often containing fragments of cell
processes (original magnification ×6900). (C)
Laminated and thickened lamina densa con-
tains small electron-dense granulations inside
the clear spaces between the layers (uranyl ac-
etate and lead cytrate; original magnification
×60,000). (D) Thickened tubular basement
membrane split into multiple, thin, electron-
dense layers (uranyl acetate and lead cytrate;
original magnification ×21,000).
In the other two families, the pedigree could also be
compatible with the most common X-linked form. In
fact, these two families were previously investigated for
COL4A5 mutation without results [22]. In family 1, the
paternal uncle of the proband had only microhematuria
and slightly impaired renal function by the age of 59 years,
and in family 4 the 45-year-old brother of the proband
had microhematuria and slightly impaired renal func-
tion. Such slow progression of disease is very unusual
in males with X-linked Alport syndrome [23], but it has
been described in autosomal-dominant Alport syndrome
[24].
Molecular analysis confirmed that in all four families
autosomal-dominant Alport syndrome segregated. Each
family had a private mutation, the first two families in
the COL4A4 gene and the second two families in the
COL4A3 gene. Three mutations affected glycine residues
in the collagenous domain, in position 957 of COL4A4
and 1045 and 1219 of COL4A3 introducing an arginine,
a valine, and a cysteine, respectively. These substitutions
resulted in the interruption of the collagen module Gly-
X-Y. One mutation in the COL4A3 gene affected a cys-
teine in the C-terminal noncollagenous region of the
protein. This substitution replaced cysteine 1634 with a
serine and would eliminate a conserved disulfide bond,
disrupting the conformation of the C-terminal noncol-
lagenous domain.
All four probands underwent renal biopsy (Fig. 2). Two
of them had thickening and splitting of the GBM (aged
30 and 37 years, respectively), while one (age 51 years)
showed only thinning and one (age 36 years) showed only
splitting of the GBM. This latter observation is consistent
with the overlapping of microscopic changes between
Alport and thin basement membrane disease, a condi-
tion which is considered to have a benign prognosis. As
a matter of fact, even the molecular abnormalities be-
tween these two conditions widely overlap, since both
are due to heterozygous mutation in either the COL4A4
or COL4A3 gene [20, 25]. As a whole, these results indi-
cated that a correct final diagnosis cannot be derived from
electron microscopy changes alone or from molecular di-
agnosis alone, or from the use of both. A combination of
electron microscopy changes, molecular alteration, and
clinical outcome in relatives may eventually reach the
correct diagnosis. Because of this conclusion, every ef-
fort must be made to widen the pedigree of patients, and
to examine relatives.
This paper shows the clinical outcome of 25 carriers
of COL4A4 or COL4A3 mutations. None of the patients
had ocular abnormalities (Table 1). Ocular abnormalities
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Table 1. Summary of clinical findings of heterozygotes and correlation with mutated gene
Family/Individual Gender Age Hematuria Proteinuria Renal function findings Ocular Hearing Mutated gene
1/I-1 F 41a ND ND ESRD at 41 years ND ND COL4A4
1/II-1 M 65 Micro- None CFR ND ND COL4A4
1/II-3 M 59 Micro- Yes ESRD at 52 years Normal Normal COL4A4
1/III-1 F 31 Micro- None Normal Normal Normal COL4A4
1/IV-2 M 1 Micro- None ND ND ND COL4A4
2/I-1 M 90 None None Normal Normal Normal COL4A4
2/II-2 M 45 Micro-/macro- None Normal Normal BSH COL4A4
2/II-4 M 51 Micro-/macro- None Normal Normal BSH COL4A4
2/III-1 M 13 Micro-/macro- None Normal Normal Normal COL4A4
3/I-1 F 88a ND ND ESRD at 84 years ND BSH COL4A3
3/II-3 F 68 Micro- None CRF Normal Normal COL4A3
3/II-5 M 55 Micro- Yes CRF Normal BSH COL4A3
3/III-2 M 44 Micro- None Normal Normal Normal COL4A3
3/III-4 M 37 Micro- None Normal Normal Normal COL4A3
3/III-5 F 32 Micro- None Normal Normal Normal COL4A3
3/III-6 M 24 Micro- None Normal Normal Normal COL4A3
3/III-7 M 21 Micro- None Normal Normal Normal COL4A3
3/III-8 M 11 None None Normal Normal Normal COL4A3
4/I-1 F 72a ND ND ESRD at 70 years ND ND COL4A3
4/II-1 M 49 Micro-/Macro- Yes ESRD at 45 years Normal Normal COL4A3
4/II-2 M 46 Micro- None CRF Normal Normal COL4A3
4/II-3 M 45 Micro- None Normal Normal BSH COL4A3
4/II-4 M 36 Micro- None Normal Normal Normal COL4A3
4/III-1 F 20 Micro- None Normal Normal Normal COL4A3
4/III-3 F 22 None None Normal Normal Normal COL4A3
Abbreviations are: ESRD, end-stage renal disease; CRF, chronic renal failure; BSH, bilateral sensorineural hypoacusia; ND, not determined.
aDeceased.
occur in a minority of patients even in the X-linked forms,
present in the 35.2% of male and 15% of female patients
[23, 26]. Four patients (19%) had bilateral sensorineural
hypoacusia. In the X-linked form the risk of developing
deafness before the age of 40 years is about 90% in male
patients vs. only 10% in females. Very few patients (2 of
22) (9%) had proteinuria compared to 95% of males and
75% of females affected by the X-linked form. Five pa-
tients (22%) had episodes of macrohematuria compared
to 62% of males affected by the X-linked form and this oc-
curred at an older age [22–26] compared to that reported
in the X-linked form [23, 26].
In the X-linked form, 70% of male patients at the age
of 30 years and nearly 90% at 40 years had reached ESRD
[23]. In contrast, nearly all female patients had function-
ing kidneys at 30 years and only 12% had reached ESRD
at 40 years. However, after the age of 60 years, 30% to
40% had developed ESRD [26]. In our cohort of pa-
tients affected by autosomal-dominant Alport syndrome,
all had functioning kidneys at the ages of 30 and 40 years.
However, after the age of 50 years, three out of eight
patients (37.5%) developed ESRD and three began to
develop CRF, while one patient had isolated microhe-
maturia and another, aged 90 years, was asymptomatic.
In conclusion, regarding the progression of renal dam-
age, autosomal-dominant Alport syndrome seems to be
milder than the X-linked form, confirming the previous
observation of Pochet et al [24]. The progression of re-
nal damage is more similar to that found in females af-
fected by the X-linked form. In addition, the autosomal-
dominant form has a wider variability.
Finally, three out of 25 mutation carriers, aged 12,
22, and 90 years, respectively, were completely asymp-
tomatic. Nonpenetrance (lack of microhematuria or
other symptoms) in the X-linked form was never reported
in affected males, and it is extremely rare in females in
which penetrance of microhematuria or other symptoms
is reported at 97.4% or 301/309 cases [26]. The present
study suggests that a reduced penetrance of about 95%
(22/25) should be considered for the autosomal-dominant
form. This has important implications for counselling and
precise risk assessment. A positive prenatal molecular di-
agnosis could lead to the abortion of 10% of completely
healthy fetuses. This observation is particularly relevant
due to the ever-increasing genetic testing for Alport syn-
drome, and because about 20% to 50% of the people
interviewed found abortion to be acceptable in cases of
an affected fetus [27–29].
This paper confirms that autosomal-dominant Alport
syndrome may be due to mutations either in the COL4A4
or COL4A3 gene. Although these data need to be con-
firmed in a larger cohort of patients, the two forms seem
to be undistinguishable from a clinical point of view
(Table 1). In addition, most phenotype variability is in-
trafamilial instead of interfamilial and the progression
of renal damage does not correlate with the kind of
mutation. In fact, this observation suggests that other
factors, beside COL4A4 or COL4A3 mutation, may
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influence the clinical outcome. These factors may or may
not be of genetic nature (lifestyle, diet). COL4A4 and
COL4A3 genes contain several polymorphisms [20]. It
could be interesting to test whether some of them are
functional variants and whether they are responsible for
part of the phenotypic variability. In addition, functional
variants in other proteins that are key players in renal fil-
tration (for examples, nephrin or podocin) may act as
modifiers. Patients with more or less proteinuria may
have more or less functioning variants of these proteins.
CONCLUSION
Investigation of COL4A3 and COL4A4 might be con-
sidered in all cases with male to male transmission and in
all cases in which analysis of the COL4A5 gene was neg-
ative, especially if careful assessment of relatives reveals
some milder affected males. The improvement of molec-
ular diagnosis may eventually results in the finding that
the autosomal-dominant form is not rare as previously
thought.
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